>…your statement above "created the impression (perhaps intentionally)" that DNDN was acting in a mindless and criminal manner…<
Neither mindless nor criminal but not necessarily the whole truth. Is it really so hard to imagine that DNDN is capable of that?
>…when, in fact, you had not a shred of evidence<
Biotech investing is not generally based on evidence per se but rather on inferences. It’s because of inferences that people like PGS and I came to the right conclusion two years ago about the outcome of the Provenge BLA and it’s because of the inability to draw such inferences that people like you came to the wrong conclusion.
Now, history seems to be repeating itself as you argue that DNDN could not possibly be frosting the Halabi output. First you stated that DNDN did not even have access to the data to play with the Halabi projected median survival in 9902b.
Now, you’ve backed off from that and your new argument seems to be that DNDN could not have frosted the Halabi data because, heck, that would be wrong. When it comes to DNDN, this kind of reasoning has consistently been a loser.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”